WO2010002655A3 - Pyrimidine derivatives as kinase inhibitors - Google Patents

Pyrimidine derivatives as kinase inhibitors Download PDF

Info

Publication number
WO2010002655A3
WO2010002655A3 PCT/US2009/048428 US2009048428W WO2010002655A3 WO 2010002655 A3 WO2010002655 A3 WO 2010002655A3 US 2009048428 W US2009048428 W US 2009048428W WO 2010002655 A3 WO2010002655 A3 WO 2010002655A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyrimidine derivatives
kinase inhibitors
analplastic
igf
alk
Prior art date
Application number
PCT/US2009/048428
Other languages
French (fr)
Other versions
WO2010002655A2 (en
Inventor
Thomas H. Marsilje Iii
Wenshuo Lu
Bei Chen
Xiaohui He
Christian Cho-Hua Lee
Songchun Jiang
Kunyong Yang
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN200980129642.9A priority Critical patent/CN102112467B/en
Priority to BRPI0914545A priority patent/BRPI0914545A2/en
Priority to JP2011516576A priority patent/JP5508412B2/en
Priority to CA2729495A priority patent/CA2729495C/en
Priority to EA201100077A priority patent/EA020730B1/en
Priority to EP09736712A priority patent/EP2318392A2/en
Priority to NZ590602A priority patent/NZ590602A/en
Priority to MX2010014039A priority patent/MX2010014039A/en
Priority to US13/000,955 priority patent/US8519129B2/en
Priority to AU2009264934A priority patent/AU2009264934B2/en
Application filed by Irm Llc filed Critical Irm Llc
Priority to UAA201104068A priority patent/UA101057C2/en
Priority to KR1020117001746A priority patent/KR101432352B1/en
Priority to BRPI0914652A priority patent/BRPI0914652A2/en
Publication of WO2010002655A2 publication Critical patent/WO2010002655A2/en
Publication of WO2010002655A3 publication Critical patent/WO2010002655A3/en
Priority to IL210124A priority patent/IL210124A0/en
Priority to CU2010000259A priority patent/CU23952B1/en
Priority to TNP2010000602A priority patent/TN2010000602A1/en
Priority to ZA2011/00344A priority patent/ZA201100344B/en
Priority to MA33549A priority patent/MA32497B1/en
Priority to US13/948,356 priority patent/US8859574B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention provides novel pyrimidine derivatives of formula I and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin- like growth factor (IGF-IR) or analplastic lymphoma kinase (ALK).
PCT/US2009/048428 2008-06-25 2009-06-24 Compounds and compositions as kinase inhibitors WO2010002655A2 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
UAA201104068A UA101057C2 (en) 2008-06-25 2009-06-24 Pyrimidine derivatives as kinase inhibitors
BRPI0914545A BRPI0914545A2 (en) 2008-06-25 2009-06-24 compounds and compositions as kinase inhibitors
CA2729495A CA2729495C (en) 2008-06-25 2009-06-24 Pyrimidine derivatives as kinase inhibitors
EA201100077A EA020730B1 (en) 2008-06-25 2009-06-24 Pyrimidine derivatives as kinase inhibitors
EP09736712A EP2318392A2 (en) 2008-06-25 2009-06-24 Pyrimidine derivatives as kinase inhibitors
NZ590602A NZ590602A (en) 2008-06-25 2009-06-24 Pyrimidine derivatives as kinase inhibitors
MX2010014039A MX2010014039A (en) 2008-06-25 2009-06-24 Pyrimidine derivatives as kinase inhibitors.
KR1020117001746A KR101432352B1 (en) 2008-06-25 2009-06-24 Pyrimidine derivatives as kinase inhibitors
AU2009264934A AU2009264934B2 (en) 2008-06-25 2009-06-24 Pyrimidine derivatives as kinase inhibitors
CN200980129642.9A CN102112467B (en) 2008-06-25 2009-06-24 Pyrimidine derivative as kinase inhibitors
JP2011516576A JP5508412B2 (en) 2008-06-25 2009-06-24 Pyrimidine derivatives as kinase inhibitors
US13/000,955 US8519129B2 (en) 2008-06-25 2009-06-24 Pyrimidine derivatives as kinase inhibitors
BRPI0914652A BRPI0914652A2 (en) 2008-06-25 2009-06-24 compounds and compositions as kinase inhibitors
IL210124A IL210124A0 (en) 2008-06-25 2010-12-20 Pyrimidine derivatives as kinase inhibitors
CU2010000259A CU23952B1 (en) 2009-02-25 2010-12-23 PIRIMIDINE DERIVATIVES AS QUINASA INHIBITORS
TNP2010000602A TN2010000602A1 (en) 2009-06-24 2010-12-24 Pyrimidine derivatives as kinase inhibitors
ZA2011/00344A ZA201100344B (en) 2008-06-25 2011-01-13 Pyrimidine derivatives as kinase inhibitors
MA33549A MA32497B1 (en) 2008-06-25 2011-01-21 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS
US13/948,356 US8859574B2 (en) 2008-06-25 2013-07-23 Compounds and compositions as kinase inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US7558308P 2008-06-25 2008-06-25
US61/075,583 2008-06-25
US15543409P 2009-02-25 2009-02-25
US61/155,434 2009-02-25

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/000,955 A-371-Of-International US8519129B2 (en) 2008-06-25 2009-06-24 Pyrimidine derivatives as kinase inhibitors
US13/948,356 Continuation US8859574B2 (en) 2008-06-25 2013-07-23 Compounds and compositions as kinase inhibitors

Publications (2)

Publication Number Publication Date
WO2010002655A2 WO2010002655A2 (en) 2010-01-07
WO2010002655A3 true WO2010002655A3 (en) 2010-04-01

Family

ID=41349515

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/048428 WO2010002655A2 (en) 2008-06-25 2009-06-24 Compounds and compositions as kinase inhibitors

Country Status (29)

Country Link
US (2) US8519129B2 (en)
EP (1) EP2318392A2 (en)
JP (1) JP5508412B2 (en)
KR (1) KR101432352B1 (en)
CN (1) CN102112467B (en)
AR (1) AR072787A1 (en)
AU (1) AU2009264934B2 (en)
BR (1) BRPI0914652A2 (en)
CA (1) CA2729495C (en)
CL (1) CL2009001476A1 (en)
CO (1) CO6351787A2 (en)
CR (1) CR20110028A (en)
DO (1) DOP2010000397A (en)
EA (1) EA020730B1 (en)
EC (1) ECSP11010784A (en)
GE (1) GEP20125564B (en)
HN (1) HN2010002733A (en)
IL (1) IL210124A0 (en)
MA (1) MA32497B1 (en)
MX (1) MX2010014039A (en)
NI (1) NI201000219A (en)
NZ (1) NZ590602A (en)
PA (1) PA8834001A1 (en)
PE (1) PE20100087A1 (en)
SV (1) SV2010003776A (en)
TW (1) TW201000466A (en)
UY (1) UY31929A (en)
WO (1) WO2010002655A2 (en)
ZA (1) ZA201100344B (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0815979A2 (en) 2007-08-28 2017-06-13 Irm Llc kinase inhibitor compounds and compositions, as well as their use
UY31929A (en) * 2008-06-25 2010-01-05 Irm Llc COMPOUNDS AND COMPOSITIONS AS CINASE INHIBITORS
US8445505B2 (en) 2008-06-25 2013-05-21 Irm Llc Pyrimidine derivatives as kinase inhibitors
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
EP2464633A1 (en) 2009-08-14 2012-06-20 Boehringer Ingelheim International GmbH Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
EP2544672A1 (en) 2010-03-09 2013-01-16 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
CA2798578C (en) 2010-05-21 2015-12-29 Chemilia Ab Novel pyrimidine derivatives
CN103038230B (en) 2010-06-04 2016-05-25 霍夫曼-拉罗奇有限公司 As the aminopyridine derivative of LRRK2 conditioning agent
NO2638031T3 (en) 2010-11-10 2018-03-10
WO2012097479A1 (en) * 2011-01-21 2012-07-26 Abbott Laboratories Bicyclic inhibitors of anaphastic lymphoma kinase
ES2587864T3 (en) 2011-03-24 2016-10-27 Noviga Research Ab Pyrimidine derivatives
CN106946795B (en) 2011-04-22 2020-06-02 西格诺药品有限公司 Substituted diaminocarboxamides and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
EP2554544A1 (en) * 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
CN104394868A (en) * 2012-04-20 2015-03-04 安基生技制药股份有限公司 Cyclopropanecarboxylate esters of purine analogues
SG11201408324QA (en) 2012-06-12 2015-01-29 Abbvie Inc Pyridinone and pyridazinone derivatives
CA2890006C (en) 2012-11-06 2021-11-23 Shanghai Fochon Pharmaceutical Co Ltd Alk kinase inhibitors
CN104109149B (en) * 2013-04-22 2018-09-28 苏州泽璟生物制药有限公司 Deuterated diaminopyrimidine compounds and the pharmaceutical composition comprising the compound
WO2015094803A1 (en) * 2013-12-16 2015-06-25 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
AU2015229103C9 (en) 2014-03-14 2020-11-26 Immutep S.A.S Antibody molecules to LAG-3 and uses thereof
EP3150592B1 (en) * 2014-05-30 2023-08-30 Shanghai Emerald Wellcares Pharmaceutical Co., LTD Alk kinase inhibitor, and preparation method and use thereof
MA41044A (en) 2014-10-08 2017-08-15 Novartis Ag COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT
MA40035A (en) 2014-10-14 2016-04-21 Dana Farber Cancer Inst Inc PD-L1 ANTIBODY MOLECULES AND THEIR USES
EP3233808B1 (en) 2014-12-16 2021-07-14 Signal Pharmaceuticals, LLC Medical uses comprising methods for measurement of inhibition of c-jun n-terminal kinase in skin
SG10202010389TA (en) 2014-12-16 2020-11-27 Signal Pharm Llc Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
CN105777616B (en) * 2014-12-26 2018-12-07 上海医药工业研究院 Synthetic intermediate of Ceritinib and preparation method thereof
WO2016123291A1 (en) 2015-01-29 2016-08-04 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
US10449211B2 (en) 2015-03-10 2019-10-22 Aduro Biotech, Inc. Compositions and methods for activating “stimulator of interferon gene”—dependent signalling
WO2017019487A1 (en) 2015-07-24 2017-02-02 Celgene Corporation Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
EP3964528A1 (en) 2015-07-29 2022-03-09 Novartis AG Combination therapies comprising antibody molecules to lag-3
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
BR112018008867A8 (en) 2015-11-03 2019-02-26 Janssen Biotech Inc antibodies that specifically bind to pd-1 and their uses
AU2016369537B2 (en) 2015-12-17 2024-03-14 Novartis Ag Antibody molecules to PD-1 and uses thereof
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
UY37695A (en) 2017-04-28 2018-11-30 Novartis Ag BIS 2’-5’-RR- (3’F-A) (3’F-A) CYCLE DINUCLEOTIDE COMPOUND AND USES OF THE SAME
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
UY38247A (en) 2018-05-30 2019-12-31 Novartis Ag ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES
US20210369714A1 (en) * 2018-09-27 2021-12-02 The Regents Of The University Of California Prevention and Treatment of Osteoarthritis by Inhibition of Insulin Growth Factor-1 Signaling
EP3966207B1 (en) 2019-05-10 2023-11-01 Deciphera Pharmaceuticals, LLC Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
EP3985000B1 (en) * 2019-06-28 2024-09-25 Chengdu Zenitar Biomedical Technology Co., Ltd. 2,4-disubstituted pyrimidine derivative, preparation method for same, and uses thereof
JP2022548881A (en) 2019-09-18 2022-11-22 ノバルティス アーゲー ENTPD2 Antibodies, Combination Therapy and Methods of Using Antibodies and Combination Therapy
GB201915618D0 (en) 2019-10-28 2019-12-11 Univ Oslo ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases
CN114685616B (en) * 2020-12-31 2024-03-29 哈尔滨三联药业股份有限公司 Synthesis method of triptorelin acetate
CN114276331B (en) * 2022-01-04 2023-05-23 中国药科大学 4-aminopiperidine compound and preparation method, pharmaceutical composition and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005026130A1 (en) * 2003-09-18 2005-03-24 Novartis Ag 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
WO2006074057A2 (en) * 2004-12-30 2006-07-13 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
US20060270694A1 (en) * 2005-05-03 2006-11-30 Rigel Pharmaceuticals, Inc. JAK kinase inhibitors and their uses
WO2008005538A2 (en) * 2006-07-05 2008-01-10 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
WO2008073687A2 (en) * 2006-12-08 2008-06-19 Irm Llc Compounds and compositions as protein kinase inhibitors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2274634T3 (en) 1998-08-29 2007-05-16 Astrazeneca Ab PIRIMIDINE COMPOUNDS.
WO2001007027A2 (en) 1999-07-22 2001-02-01 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives for the treatment of viral diseases
MXPA02007957A (en) 2000-02-17 2002-11-29 Amgen Inc Kinase inhibitors.
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
WO2003026664A1 (en) 2001-09-26 2003-04-03 Bayer Corporation 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
CA2523125A1 (en) 2003-03-25 2004-10-14 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
ES2421139T3 (en) 2003-07-30 2013-08-29 Rigel Pharmaceuticals, Inc. 2,4-Pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
PL1660458T3 (en) 2003-08-15 2012-07-31 Novartis Ag 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
KR100700676B1 (en) 2005-06-24 2007-03-28 (주) 비엔씨바이오팜 6-4-Substituted-anilinopyrimidine derivatives, method for preparing thereof and antiviral pharmaceutical composition comprising the same
AU2006290465A1 (en) 2005-09-15 2007-03-22 Orchid Research Laboratories Limited Novel pyrimidine carboxamides
BR122021011788B1 (en) 2005-11-01 2022-01-25 Impact Biomedicines, Inc Biaryl metapyrimidine kinase inhibitors, pharmaceutical composition and process for preparing a pharmaceutical composition
CL2007002231A1 (en) 2006-08-02 2008-04-11 Basf Ag USE OF COMPOUNDS DERIVED FROM 5- (HET) ARILPIRIMIDINE TO COMBAT DANGINE FUNGES; COMPOUNDS DERIVED FROM 5- (HET) ARILPIRIMIDINA; FUNGICIDE AGENT; AND PHARMACEUTICAL AGENT.
MY153263A (en) 2006-08-15 2015-01-29 Novartis Ag Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels
EP2684874B1 (en) 2006-10-23 2017-05-17 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors
BRPI0722383A2 (en) 2006-12-08 2012-06-05 Irm Llc protein kinase inhibiting compounds, compositions containing them as well as their uses
US20100056468A1 (en) 2007-01-08 2010-03-04 University Health Network Pyrimidine Derivatives As Anticancer Agents
WO2009017838A2 (en) 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
BRPI0815979A2 (en) 2007-08-28 2017-06-13 Irm Llc kinase inhibitor compounds and compositions, as well as their use
PE20091236A1 (en) 2007-11-22 2009-09-16 Astrazeneca Ab PYRIMIDINE DERIVATIVES AS IMMUNOMODULATORS OF TLR7
WO2009103652A1 (en) 2008-02-22 2009-08-27 F. Hoffmann-La Roche Ag Modulators for amyloid beta
UY31929A (en) * 2008-06-25 2010-01-05 Irm Llc COMPOUNDS AND COMPOSITIONS AS CINASE INHIBITORS
US8445505B2 (en) 2008-06-25 2013-05-21 Irm Llc Pyrimidine derivatives as kinase inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005026130A1 (en) * 2003-09-18 2005-03-24 Novartis Ag 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
WO2006074057A2 (en) * 2004-12-30 2006-07-13 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
US20060270694A1 (en) * 2005-05-03 2006-11-30 Rigel Pharmaceuticals, Inc. JAK kinase inhibitors and their uses
WO2008005538A2 (en) * 2006-07-05 2008-01-10 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
WO2008073687A2 (en) * 2006-12-08 2008-06-19 Irm Llc Compounds and compositions as protein kinase inhibitors

Also Published As

Publication number Publication date
DOP2010000397A (en) 2011-01-15
US8859574B2 (en) 2014-10-14
CN102112467A (en) 2011-06-29
NI201000219A (en) 2011-05-24
AU2009264934A1 (en) 2010-01-07
MX2010014039A (en) 2011-01-21
AR072787A1 (en) 2010-09-22
US8519129B2 (en) 2013-08-27
AU2009264934B2 (en) 2012-09-27
CR20110028A (en) 2011-04-07
CO6351787A2 (en) 2011-12-20
IL210124A0 (en) 2011-02-28
US20130310361A1 (en) 2013-11-21
CA2729495C (en) 2013-12-17
SV2010003776A (en) 2012-01-04
WO2010002655A2 (en) 2010-01-07
KR20110022699A (en) 2011-03-07
EA201100077A1 (en) 2011-08-30
ECSP11010784A (en) 2011-02-28
UY31929A (en) 2010-01-05
EP2318392A2 (en) 2011-05-11
PA8834001A1 (en) 2010-04-21
JP2011526284A (en) 2011-10-06
US20110112063A1 (en) 2011-05-12
HN2010002733A (en) 2013-01-28
ZA201100344B (en) 2012-10-31
NZ590602A (en) 2011-10-28
CA2729495A1 (en) 2010-01-07
TW201000466A (en) 2010-01-01
JP5508412B2 (en) 2014-05-28
KR101432352B1 (en) 2014-08-21
EA020730B1 (en) 2015-01-30
MA32497B1 (en) 2011-07-03
BRPI0914652A2 (en) 2017-06-06
PE20100087A1 (en) 2010-02-08
CN102112467B (en) 2014-04-30
GEP20125564B (en) 2012-06-25
CL2009001476A1 (en) 2010-01-11

Similar Documents

Publication Publication Date Title
WO2010002655A3 (en) Pyrimidine derivatives as kinase inhibitors
WO2009032668A3 (en) 2 -biphenylamino-4 -aminopyrimidine derivatives as kinase inhibitors
WO2009158431A3 (en) Pyrimidine derivatives as kinase inhibitors
WO2008073687A3 (en) Compounds and compositions as protein kinase inhibitors
UA100846C2 (en) Compounds and compositions as protein kinase inhibitors
WO2009126514A8 (en) Compounds and compositions as kinase inhibitors
WO2009126515A8 (en) Compounds and compositions as protein kinase inhibitors
WO2008013838A3 (en) Pyridizinone derivatives
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2008049123A8 (en) 2,4-pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases
WO2007095124A3 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
WO2008076862A3 (en) 1-substituted imidazole derivatives and their use as aldosterone synthase inhibitors
WO2009108383A3 (en) Substituted xanthine derivatives
MX2011013325A (en) 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors.
MX2012013197A (en) Indazole inhibitors of kinase.
WO2012003912A8 (en) Bipyridyl derivatives useful for the treatment of kinase - induced diseases
WO2008046919A3 (en) Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
MX2011012629A (en) Pyrimidine inhibitors of kinase activity.
WO2009156041A3 (en) Thiazolyl piperdine derivatives
MX2011012631A (en) Pyrimidine inhibitors of kinase activity.
WO2009094560A3 (en) Thienopyranones as kinase inhibitors
WO2009105969A8 (en) Epothilone analogues, their pharmaceutical compositions, their use and their preparations
MX2011012632A (en) Pyrimidine inhibitors of kinase activity.
WO2010075558A3 (en) Compositions and methods for inhibition of the jak pathway
WO2010039668A3 (en) Inhibitors of cyclin kinase inhibitor p21

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980129642.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09736712

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/014039

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 12010502859

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 210124

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2010122175

Country of ref document: EG

Ref document number: 13000955

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2729495

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: D2010259

Country of ref document: CU

ENP Entry into the national phase

Ref document number: 2011516576

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009264934

Country of ref document: AU

Ref document number: CR2011-000028

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 2009736712

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 590602

Country of ref document: NZ

Ref document number: 431/DELNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: DZP2011000052

Country of ref document: DZ

ENP Entry into the national phase

Ref document number: 20117001746

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201100077

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 12072

Country of ref document: GE

Ref document number: 11008053

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2009264934

Country of ref document: AU

Date of ref document: 20090624

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201104068

Country of ref document: UA

ENP Entry into the national phase

Ref document number: PI0914652

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20101223